top of page
Recent Research
JNJ/PTGX: JNJ2113: Oral dosing faces hurdles of new rival classes in psoriasis & Ulcerative Colitis
The injectable IL23 class has been successful in treating a wide variety of inflammatory conditions such as psoriasis and inflammatory...
Sep 18, 2023
BMY/JNJ/BAY: Milvexian moves ahead at ESC
The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...
Aug 28, 2022
PD1 Combos at ESMO good for AZN and BMY not for MRK and ROG
Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...
Oct 17, 2016
Unravelling the MYSTICal
Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...
Oct 13, 2016
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page